Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports that it bought back 650,000 ordinary shares on 19 March 2026 through BNP Paribas as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were acquired at a volume‑weighted average price of 1,954.04p, within a range of 1,944.50p to 1,975.50p per share.
The shares will be held as treasury shares. Since 17 February 2026, GSK has purchased 12,771,521 ordinary shares under this programme. After this transaction, the company holds 252,662,615 shares in treasury and has 4,063,508,150 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.22% of voting rights, a figure shareholders can use when assessing disclosure thresholds.
GSK plc filed a report describing a small insider share purchase. Chief People Officer Diana Conrad acquired American Depositary Shares under a GSK pension plan. She bought 12.430 ADS at a price of $54.4100 per ADS on 2026-03-16 on the New York Stock Exchange.
GSK plc reported that senior executive Maya Martinez-Davis, President, acquired notional American Depositary Shares through the GSK Executive Supplemental Savings Plan. The transaction involved 129.152 ADS at a price of $53.3900 per ADS on 2026-03-13 on the New York Stock Exchange.
These are plan-related notional ADS rather than a standard open-market purchase, reflecting additional equity-linked compensation within her executive savings account.
GSK plc reports that it repurchased 628,000 ordinary shares on 16 March 2026 under its existing share buyback programme, acting through BNP Paribas. The shares were bought at prices between 2,026.00p and 2,052.00p per share, with a volume‑weighted average price of 2,035.82p.
The repurchased shares will be held as treasury shares. Since 17 February 2026, GSK has bought back a total of 10,553,409 ordinary shares. After this transaction, GSK holds 250,444,503 shares in treasury and has 4,065,726,262 ordinary shares in issue, all carrying voting rights.
The total number of voting rights in GSK is stated as 4,065,726,262, and the company notes that treasury shares represent 6.16% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that on 13 March 2026 it repurchased 445,000 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. Prices ranged from 2,027.00p to 2,060.00p per share, with a volume‑weighted average price of 2,041.70p.
The shares bought will be held as treasury shares. Since 17 February 2026, GSK has repurchased 9,925,409 ordinary shares. After this transaction, it holds 249,816,503 shares in treasury and has 4,066,354,262 ordinary shares in issue and voting rights, with treasury shares representing 6.14% of voting rights.
GSK plc reports that the US FDA has expanded the approved age indication for its RSV vaccine Arexvy to adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease caused by RSV. Arexvy was previously approved in the US for adults 60 and older, and for adults 50-59 at increased risk. GSK notes that an estimated 21 million US adults under 50 have at least one risk factor for severe RSV infection, and that RSV drives about 17,000 hospitalisations and 1.97 million outpatient visits annually among adults 18-49 years. The label expansion is supported by a Phase IIIb trial showing a non-inferior immune response versus adults 60 and above, with a safety profile consistent with earlier Phase III data.
GSK plc reported that several senior leaders acquired small amounts of equity through company share plans. On March 10, 2026, executives including the President, Europe; Chief Financial Officer; Group General Counsel; President, Corporate Development; President, Global Supply Chain; President, Global Affairs; CEO, ViiV Healthcare and President, Global Health; and the SVP & Company Secretary each acquired 12 Ordinary Shares of 31¼ pence at £20.7168 per share under GSK's Share Reward Plan on the London Stock Exchange.
In a separate transaction on March 9, 2026, President Maya Martinez-Davis acquired 2.150 notional American Depositary Shares at $55.5100 within her GSK Executive Supplemental Savings Plan account on the New York Stock Exchange.
GSK plc reports that on 11 March 2026 it repurchased 513,409 ordinary shares of 31¼ pence each through BNP Paribas under its existing share buyback programme. The shares were bought between 2,047.00p and 2,078.00p at a volume-weighted average price of 2,061.69p and will be held as treasury shares.
Since 17 February 2026, GSK has repurchased 8,690,409 shares. After this transaction, it holds 248,581,503 shares in treasury and has 4,067,587,319 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.11% of voting rights.
GSK plc reports that, acting through BNP Paribas, it repurchased 505,000 ordinary shares of 31¼ pence each on 10 March 2026. The shares were bought at prices between 2,052.00p and 2,082.00p, with a volume-weighted average price of 2,066.69p per share.
The repurchased shares will be held as treasury shares as part of GSK’s existing share buyback programme under a non-discretionary agreement with the broker announced on 17 February 2026. Since that date, GSK has bought 8,177,000 shares in total under the programme.
After this transaction, GSK holds 248,068,094 shares in treasury and has 4,068,100,728 ordinary shares in issue, giving a total of 4,068,100,728 voting rights. The company confirms that treasury shares represent 6.10 per cent of its voting rights.
GSK plc reports that it bought back 516,000 of its ordinary shares on 9 March 2026 through BNP Paribas SA under its existing non-discretionary share buyback programme. The volume-weighted average price was 2,028.51p per share, within a range of 1,989.00p to 2,047.00p.
The shares purchased will be held as treasury shares. Since 17 February 2026, GSK has bought 7,672,000 ordinary shares under this programme. After this transaction, it holds 247,563,094 shares in treasury and has 4,068,605,728 ordinary shares in issue, which equals 4,068,605,728 voting rights.
GSK confirms that, following these purchases, the percentage of voting rights attributable to treasury shares is 6.08%, a figure shareholders may use when assessing notification thresholds under the UK Financial Conduct Authority’s disclosure and transparency rules.